TG Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $83,879 | $73,466 | $63,474 | $43,971 |
Gross Profit | 74,538 | 65,090 | 57,951 | 36,025 |
EBITDA | 15,100 | 10,600 | -8,308 | -12,394 |
EBIT | 15,036 | 10,528 | -8,390 | -12,485 |
Net Income | 3,880 | 6,879 | -10,707 | -14,416 |
Net Change In Cash | 83,879 | 73,466 | 63,474 | 43,971 |
Free Cash Flow | -12,229 | 5,536 | -8,207 | -13,210 |
Cash | 195,822 | 82,910 | 75,477 | 92,933 |
Basic Shares | 160,714 | 159,423 | 146,209 | 143,092 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $233,662 | $2,785 | $6,689 | $152 |
Gross Profit | 219,108 | 2,520 | 5,899 | -222 |
EBITDA | 21,056 | -187,629 | -341,969 | -272,678 |
EBIT | 20,633 | -188,144 | -342,463 | -273,052 |
Net Income | 12,672 | -203,831 | -355,552 | -285,878 |
Net Change In Cash | 233,662 | 2,785 | 6,689 | 152 |
Cost of Revenue | -196,574 | -254,547 | 440,810 | |
Free Cash Flow | -31,413 | -176,184 | -296,035 | -214,864 |
Cash | 92,933 | 102,304 | 298,887 | 553,439 |
Basic Shares | 148,508 | 135,411 | 132,222 | 115,333 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.02 |
2024-06-30 | $0.04 |
2024-03-31 | -$0.07 |
2023-12-31 | -$0.10 |
